Why Doximity Stock Is Back On Investors’ Radar

Doximity (DOCS) has drawn fresh attention after a weak share price stretch, with the stock down 15% over the past month and 19% over the past 3 months despite profitable operations.

At the latest share price of US$21.04, Doximity’s recent 7 day share price return of 3.85% comes after a period of weaker momentum. The year to date share price return is down 51.4% and the 1 year total shareholder return is down 61.44%, suggesting investors have been reassessing both growth potential and risk.

If you are comparing Doximity with other opportunities in digital health and AI, this could be a good time to scan for healthcare peers using our 39 healthcare AI stocks

With Doximity still profitable and trading at an estimated 40% discount to an intrinsic value model, yet with recent returns under pressure, you have to ask: is this a reset buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 44.3% Undervalued

Compared with the last close at $21.04, the most followed narrative pegs Doximity’s fair value at $37.77, framing the current share price as a sizeable discount.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, which in turn is expected to support long-term revenue and margin expansion.

Curious what kind of revenue runway and margin profile sit behind that valuation gap? The narrative leans on measured growth, resilient profitability, and a richer earnings multiple.

Result: Fair Value of $37.77 (UNDERVALUED)

However, analysts flag that slower revenue visibility and Doximity’s dependence on pharmaceutical marketing budgets could still challenge the undervaluation thesis if conditions tighten.

Next Steps

If this mix of weak recent returns and an undervaluation narrative leaves you torn, consider weighing the potential upside yourself with the 2 key rewards.

Looking for more investment ideas?

If Doximity has you rethinking your watchlist, now is the time to widen your search and see what other opportunities might suit your style.

• Spot potential mispricings early and compare them with Doximity by scanning the 47 high quality undervalued stocks that match your preferred fundamentals.
• Secure more predictable cash returns by reviewing companies in the 10 dividend fortresses that could complement a growth focused holding like DOCS.
• Sleep easier at night by assessing the 63 resilient stocks with low risk scores and seeing which stocks align with a more defensive approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.